TARGETING CYCLOOXYGENASE-2 WITH A TARGETED LIPOSOMAL FORMULATION FOR COLORECTAL CANCER.

Year 2017, Volume: Volume 2 Issue: İssue 1 (1) - 2.İnternational Congress Of Forensic Toxicology, 88 - 88, 16.02.2017

Sreeparna Banerjee

Abstract

Cyclooxygenase-2
(COX-2) is highly expressed in many different cancers; particularly in
colorectal cancer (CRC). Liposomal drug delivery systems can be used to
increase the therapeutic efficacy of CLX while minimizing its side effects.
Cetuximab (anti-Epidermal Growth Factor Receptor -EGFR- monoclonal antibody) is
a promising targeting ligand since EGFR is highly expressed in a wide range of
solid tumors. Dual targeting of EGFR and COX-2 signaling may have additive or
synergistic effects. Here, we describe an EGFR-targeted immunoliposome for
enhancing the delivery of CLX to cancer cells. 
Cell association studies indicated that the immunoliposome uptake was
higher in EGFR-overexpressing cells compared to the non-targeted liposomes. In
addition, the CLX-loaded-anti-EGFR immunoliposomes were significantly more
toxic compared to the non-targeted ones in cancer cells with EGFR-overexpression
but not in the cells with low EGFR expression, regardless of their COX-2
expression status. Thus, selective targeting of CLX with anti-EGFR
immunoliposomes appears to be a promising strategy for therapy of tumors that
overexpress EGFR.

 

 BAP-07-02-2014-004 and TÜBA-GEBİP

Keywords

TARGETING CYCLOOXYGENASE-2 WITH A TARGETED LIPOSOMAL FORMULATION FOR COLORECTAL CANCER.

References

• Sreeparna BANERJEE Department of Biological Sciences, Middle East Technical University, Ankara, Turkey